A vaccine for type 1s will be tested on 18 human volunteers with type 1 this summer in the United Kingdom. Researchers at the University of Bristol in southwest England and King’s College in London say that the vaccine could be on the market in 10 years’ time.
The vaccine, developed by CLinalfa, a part of the Merck pharmaceutical group, has a molecule that is identical to part of the islets. When this molecule is added to human blood, it stops white blood cells from destroying pancreatic insulin-producing islets.
Trials with the vaccine have been successful in mice.
* * *
Sources: Medical News Today, Agence France Presse, Diabetes U.K.